drugset / Trial / NCT00593554
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.
Timeline
- Start
- 2007-08-07
- Primary completion
- 2016-08-27
- Completion
- 2017-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palifermin | Protein / enzyme biologic | 60 ug/kg | — |
| Background | Fludarabine | Small molecule | 40 mg/m2 | — |
| Background | Thiotepa | Other / unclassified | 5 mg/kg | — |
| Background | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | — |